• Asunaprevir (BMS-650032) Assay Guide

  2026-08-17

  A scenario-based guide to using Asunaprevir (BMS-650032), SKU A3195, in HCV RNA replication, cell viability, proliferation, and cytotoxicity workflows. It connects mechanism, solvent handling, controls, endpoint interpretation, and practical product-selection criteria to improve assay reproducibility.

• Recombinant Human Oncostatin M Assay Workflows

  2026-08-17

  Build reproducible proliferation and cytokine-response assays with a tag-free, highly active OSM preparation. This guide connects practical rh-Oncostatin M handling with phenotype-aware experimental design inspired by recent neuroinflammation research.

• N-MYC/eIF4G1 Survival Axis in inv(16) AML

  2026-08-16

  Peramangalam et al. identify a previously unrecognized MYCN enhancer and establish an N-MYC/eIF4G1 pathway that supports survival in inv(16) acute myeloid leukemia. By integrating transcriptomic, regulatory, cellular, and patient-derived model data, the study connects CBFβ-SMMHC disruption to a specific leukemic survival program and provides a framework for mechanism-led AML research.

• Candida krusei Forms Trigger Distinct BMEC Apoptosis

  2026-08-15

  The reference study shows that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but through different dominant pathways. Its phase-resolved co-culture design links yeast-associated injury to mitochondrial dysfunction and hypha-associated injury to death ligand/receptor signaling, while identifying TLR2/ERK and JNK/ERK signaling as shared regulatory axes.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-08-14

  The reference study identifies a miR-18a/ALOXE3 regulatory axis that promotes glioblastoma by weakening ferroptotic cell death and enhancing tumor-cell migration through 12-HETE signaling. Its integrated genetic, cellular, lipid-mediator, and orthotopic-model evidence positions ALOXE3 as a mechanistic link between lipid metabolism, p53-associated ferroptosis, and glioblastoma progression.

• Spinal Astrocytic EAATs in Breakthrough Cancer Pain

  2026-08-14

  Jiang and colleagues developed a recurrent endothelin-1 mouse model of breakthrough cancer pain and identified coordinated changes in spinal astrocytic EAATs and connexin 43 signaling. Their findings position glutamate transport and Cx43-associated gap junction activity as experimentally tractable mechanisms, while highlighting Gap26 as a pharmacological tool for testing this relationship.

• LEE011 succinate: CDK Inhibitor Workflow

  2026-08-13

  Build more informative cancer research assays with LEE011 succinate, a selective CDK4/6 inhibitor suited to proliferation, cell-cycle, and combination studies. This guide connects practical dosing and plate-based workflows with pH-aware formulation controls and troubleshooting strategies.

• Nifedipine: Calcium Signaling Meets Liver Pharmacology

  2026-08-13

  Nifedipine (BAY-a-1040) is more than an L-type calcium channel blocker: it is a precise perturbation tool for separating calcium-dependent phenotypes from hepatic metabolic adaptation. This guide connects calcium influx inhibition with PXR–CYP assay design while defining practical controls, handling, and translational limits.

• PR-619: Reversible DUB Inhibitor

  2026-08-12

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for ubiquitination pathway research. It broadly inhibits cysteine-dependent DUBs, increases cellular ubiquitinated proteins without directly blocking proteasomal catalytic activity, and supports cancer biology, autophagy, and neurodegeneration studies.

• Octenidine dihydrochloride Research Workflows

  2026-08-12

  Octenidine dihydrochloride provides a practical benchmark for membrane-focused antimicrobial assays, from planktonic killing and biofilm testing to comparative antiseptic research. This guide pairs preparation details with assay controls, troubleshooting strategies, and recent gemini-quaternary-ammonium findings to help researchers distinguish solubility, exposure, and biological effects.

• Cyanin Chloride in a HaCaT Psoriasis Model

  2026-08-11

  The 2024 study by Kim and colleagues examines cyanin chloride in inflammatory and barrier-defective skin-cell models, combining antioxidant assays, macrophage inflammation testing, cytokine-stimulated HaCaT keratinocytes, STAT3 analysis, and transepithelial electrical resistance measurements. Its central contribution is to connect suppression of psoriasis-associated inflammatory signals with restoration of epithelial barrier markers, while also clarifying the limits of translating in vitro findings into therapeutic claims.

• Agatoxin-Sensitive Channels in Cardiac Vagal Neurons

  2026-08-11

  Wang, Irnaten, and Mendelowitz used whole-cell patch-clamp recordings and selective calcium-channel antagonists to show that nicotine activates cardiac vagal neurons through agatoxin-IVA-sensitive voltage-dependent calcium channels. The study separates presynaptic facilitation of glutamatergic release from the postsynaptic inward current, providing a focused pharmacological framework for analyzing nicotinic control of cardiac autonomic circuits.

• BGJ398: FGFR Workflow for Cancer Research

  2026-08-10

  BGJ398 (NVP-BGJ398) combines nanomolar FGFR1/2/3 potency with a practical workflow for pathway validation, cancer-cell response profiling, and carefully controlled developmental explant studies. This guide connects target engagement, apoptosis readouts, species-aware assay design, and troubleshooting without treating preclinical findings as clinical guidance.

• EZ Cap™ Human PTEN mRNA (ψUTP) Workflow

  2026-08-09

  Build reproducible PTEN restoration studies with Cap 1, pseudouridine-modified in vitro transcribed mRNA designed for efficient mammalian translation. This practical guide connects formulation, pathway readouts, resistance models, and troubleshooting to the nanoparticle-based strategy reported in breast cancer research.

• GSK126: Selective EZH2 Inhibitor Guide

  2026-08-08

  GSK126 is a potent, selective EZH2 inhibitor for studying PRC2-dependent H3K27me3 and gene silencing. Its strongest research rationale is in EZH2-mutant lymphoma models, while broader oncology applications require context-specific validation.

15891 records 1/1060 page Next 12345 下5页 Last page